ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 554

Evidence to Guide Glucocorticoid Tapering Is Lacking in RA

Beth Wallace1, David Wallace 2, Akbar Waljee 3 and Daniel Clauw 4, 1Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 2Division of General Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 3Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 4Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: glucocorticoids, taper and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Treatments Poster I: Novel Treatments

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Over a third of RA patients are managed with long-term oral glucocorticoids (GC), defined as daily GC use for ≥3 months[1]. Due to dose-dependent toxicity concerns, current ACR guidelines for RA management recommend tapering GC when possible[2]. Despite this, GC tapering is under-studied in RA. This is particularly true among patients with established RA ( >2 years’ duration) who use long-term GC. These patients often have high cumulative GC exposure levels and GC-associated comorbidities, and are prone to withdrawal symptoms when GC are tapered. Our aim was to review existing clinical trials that evaluate GC tapering in RA.

Methods: We searched clinicaltrials.gov for registered studies of oral GC use in RA patients since 2008 (Fig. 1). In addition, we reviewed studies captured by a previous systematic review of clinical trials of GC tapering in RA, which included years 1972 to 2011 [3].

Results: Results: 2300 entries from clinicaltrials.gov were screened (Fig. 1-2). 179 entries evaluated GC, and 11 evaluated oral GC tapering. Five additional studies were identified from the previous systematic review, for a total of 16 studies. Of the 11 clinicaltrials.gov entries, seven incorporated GC tapers as induction treatment or bridge therapy for early RA patients (Table 1). Two entries did not specify starting GC dose or taper duration. One entry (NCT02573012) compared RA disease activity among patients on tocilizumab randomized to continue vs. stop vs taper off long-term oral GC. The last (NCT02997605) compared efficacy of prednisone vs. hydrocortisone tapers in allowing RA patients to discontinue long-term oral GC. Of the five studies identified from the previous systematic review, three incorporated GC tapers as induction treatment for early RA patients. The remaining two studies compared RA disease activity (Tengstrand et al) or radiographic progression (Pincus et al) among patients randomized to continue vs taper off long-term GC.  Of the 16 studies reviewed, only one (NCT02997605) evaluated GC withdrawal symptoms as a secondary outcome. Another (Tengstrand et al) allowed for slower GC taper if “withdrawal symptoms” occurred, but did not specify how these were defined.

Conclusion: There is little published trial data to guide clinicians attempting to taper long-term GC among patients with established RA. We identified only one trial directly comparing two GC tapering regimens, which is currently unpublished. Further work is needed to develop data-driven protocols for GC tapering that account for GC withdrawal symptoms.

  1. Wallace B, Lin P, Kamdar N, Noureldin M, Hayward R, Fox DA, et al. Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population [abstract]. Arthritis & rheumatology. 2018; 70(Suppl. 10).
  2. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & rheumatology. 2016 Jan; 68(1):1-26.
  3. Volkmann ER, Rezai S, Tarp S, Woodworth TG, Furst DE. We still don’t know how to taper glucocorticoids in rheumatoid arthritis, and we can do better. The Journal of rheumatology. 2013 Oct; 40(10):1646-1649.

Figure 1: Study selection

Figure 2: Search strategy from clinicaltrials.gov -4/18/19-


table 1 acr abstract clinicaltrials.gov

Table 1: Included studies


Disclosure: B. Wallace, None; D. Wallace, None; A. Waljee, None; D. Clauw, Aptinyx, 2, 5, Daiichi Sankyo, 5, Daiichi Snakyo, 5, Eli Lilly, 5, Intec Pharma, 5, Nix Paterson LLP, 8, Nix Patterson LLP, 8, Pfizer, 2, 5, Pfizer Inc, 2, 5, 8, Samumed, 5, Theravance, 5, Tonix, 5, Williams & Connolly LLP, 8, Williams and Connolly LLP, 8, Zynerba, 5.

To cite this abstract in AMA style:

Wallace B, Wallace D, Waljee A, Clauw D. Evidence to Guide Glucocorticoid Tapering Is Lacking in RA [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evidence-to-guide-glucocorticoid-tapering-is-lacking-in-ra/. Accessed January 18, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-to-guide-glucocorticoid-tapering-is-lacking-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.